Sulfatinib is an oral drug candidate that selectively inhibits the tyrosine kinase activity associated with VEGFR and fibroblast growth receptor 1, or FGFR1, a receptor for a protein which also plays a role in tumor growth. Our published expanded Phase I clinical data indicates that sulfatinib has the highest objective response rate, or the proportion of patients with tumor shrinkage of more than 38%, reported to date in patients with neuroendrocrine tumors. An objective response rate of 35% was observed for sulfatinib in this study, compared to less than 10% for sunitinib and everolimus, the two approved single agent therapies for neuroendocrine tumors.
We currently retain all rights to sulfatinib worldwide. It is the first oncology candidate that we have taken through proof-of-concept in China and expanded to a U.S. clinical study ourselves. It is now in clinical development in the United States and China. Based on sulfatinib’s mechanism of action, in addition to neuroendocrine tumors we also plan to explore other indications, such as thyroid cancer.